![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
HepDART December 2013 Selected Slide Presentations
|
|
|
HepDart 2013 December, Hawaii, Selected Slide Presentations
http://www.informedhorizons.com/hepdart2013/presentations.aspx
State of the Art Presentation
Innovations in HCV Therapy
Ira Jacobson, Weill Cornell Medical College, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Jacobson_final_122713.pdf
![HepDart1.gif](../../2014/images/012414/012414-3/HepDart1.gif)
Hepatitis C: The Tides Are Shifting
Deploying Nucleoside Therapy to Eradicate HCV
John McHutchison, Gilead Sciences Inc., USA
Simeprevir Overview: From IFN-Containing to IFN-Free Regimens
Gastón Picchio, Janssen R&D, USA
Daclatasvir Present and Future DAA Combinations
Douglas Manion, Bristol-Myers Squibb, USA
Efficacy and Resistance Profile of the next Generation Protease Inhibitor MK5172 in IFN-free Phase 2 Studies of GT1 Infection
Daria Hazuda, Merck Research Laboratories, USA
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus Infection (HCV)
Douglas Mayers, Idenix Pharmaceuticals, Inc., USA
Discovery and Development of a Second Generation Direct-Acting Antiviral Portfolio for Chronic Hepatitis C:
An Update on Achillion's Protease Inhibitor (Sovaprevir), NS5A Inhibitor (3102) and Nucleotide Inhibitor (3422) Regimen Strategy
David Apelian, Achillion Pharmaceuticals, Inc., USA
The Future of HCV Therapy: Patient-Tailored Treatment or One-Size Fits All?
Wulf Otto Böcher, Boehringer Ingelheim Pharma GmbH & Co KG, Germany
High Sustained Virologic Response Rates with Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions
Mark Sulkowski, The Johns Hopkins University School of Medicine, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Sulkowski_HepDart Oral Sulkowski_9Dec13_FINAL Tuesday.pdf
Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir
and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection
Richard Colonno, Presidio Pharmaceuticals, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Colonno.pdf
A Fixed Dose Combination of Sofosbuvir and Ledipasvir is Highly Effective in Treatment-Naïve and Treatment Experienced
Genotype 1 HCV infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies
Eric Lawitz, Texas Liver Institute and University of Texas Health Science Center, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Lawitz HEPDART 2013_5Dec13_to client.pdf
Simeprevir with Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 4 Infection in Treatment-Naïve or -Experienced Patients: Interim Results of a Phase III Trial
Christophe Moreno, ULB Hôpital Erasme, Belgium
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Moreno_Website.pdf
Lymphomas Associated with HCV
Jordan Feld, University of Toronto, Canada
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Feld_MAC NHL Lymphoma & HCV HepDart 2013.pdf
HCV and Diabetes
Francesco Negro, University Hospitals of Geneva, Switzerland
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Negro HCV diabetes HepDART 2013.pdf
State of the Art Presentation
Epidemiology and Outcome of Viral Hepatitis B and C in the US
W. Ray Kim, Stanford University, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Kim_MAC_Website.pdf
![HepDart2.gif](../../2014/images/012414/012414-3/HepDart2.gif)
![HepDart3.gif](../../2014/images/012414/012414-3/HepDart3.gif)
![HepDart4.gif](../../2014/images/012414/012414-3/HepDart4.gif)
![HepDart5.gif](../../2014/images/012414/012414-3/HepDart5.gif)
Breaking Down the Barriers to HCV Treatment among People Who Inject Drugs
Jason Grebely, University of New South Wales, Australia
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Grebely HEP DART 2013_06Dec13.pdf
![HepDart6.gif](../../2014/images/012414/012414-3/HepDart6.gif)
![HepDart7.gif](../../2014/images/012414/012414-3/HepDart7.gif)
![HepDart8.gif](../../2014/images/012414/012414-3/HepDart8.gif)
Special Lecture: Off Label Combinations: Collaborative versus Incestuous
Donald Jensen, University of Chicago, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Jensen_REVISED Off Label Combinations.pdf
![HepDart9.gif](../../2014/images/012414/012414-3/HepDart9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|